https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=13505
No pharmaceutical opinion available for this interaction.
Carbamazepine can induce the metabolism (CYP 3A4) and decrease the plasma concentration of Cobicistat.
Cobicistat may possibly inhibit the metabolism (CYP 3A4) and consequently increase the plasma concentration of Carbamazepine.
Possible decrease of the pharmacokinetic boosting effect.
Therefore, resulting in loss of therapeutic effect of associated IP.
Monitor for signs and symptoms of therapeutic failure.
–
Possible increase of adverse effects.
Contraindicated. Use alternative.
Gabapentin, pregabaline, leviracetam.
Carbamazepine adverse effects : disorientation, ataxia, lethargy, drowsiness, nausea, vomiting, headache, diplopia, dizziness, leukopenia and hyponatremia.
Carbamazepine
Associated PI plasma level
CD4+
Viral load HIV
–
See carbamazepine + elvitegravir/cobicistat.
Ref #1304 : Reported case of a 20-year-old patient who developed vomiting, dizziness, elevated liver enzymes, and increased carbamazepine concentration by 87% following the addition of one dose of ritonavir 200 mg. Symptoms started within 12 hours after the first dose of ritonavir. In order to obtain a concentration within the therapeutic index, the dose of carbamazepine was reduced from 750 to 280 mg QD. Several other cases of acute toxicity to carbamazepine 2 to 4 days after the addition of ritonavir have been reported. See ritonavir + carbamazepine.
Ref #2090: Another case reported of a 50 year man who developed excessive drowsiness following the introduction of lopinavir/ritonavir and it was found that his serum carbamazepine concentration had increased by 46%. His antiretroviral therapy was then changed to nelfinavir 1250 mg BID but 3 days later the same symptoms appeared with 53% increase in carbamazepine. The symptoms of carbamazepine toxicity disappeared after a carbamazepine dose reduction of 33%. See lopinavir/ritonavir + carbamazepine.